Verona Pharma Statistics
Share Statistics
Verona Pharma has 81.83M shares outstanding. The number of shares has increased by -86.79% in one year.
| Shares Outstanding | 81.83M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.92% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 68.91M |
| Failed to Deliver (FTD) Shares | 3.58K |
| FTD / Avg. Volume | 0.33% |
Short Selling Information
The latest short interest is 6.63M, so 8.1% of the outstanding shares have been sold short.
| Short Interest | 6.63M |
| Short % of Shares Out | 8.1% |
| Short % of Float | 9.61% |
| Short Ratio (days to cover) | 6.56 |
Valuation Ratios
The PE ratio is -28.98 and the forward PE ratio is -138.36.
| PE Ratio | -28.98 |
| Forward PE | -138.36 |
| PS Ratio | 0 |
| Forward PS | 11.6 |
| PB Ratio | 6.32 |
| P/FCF Ratio | -31.38 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Verona Pharma.
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 33.33, with a Debt / Equity ratio of 0.21.
| Current Ratio | 33.33 |
| Quick Ratio | 33.33 |
| Debt / Equity | 0.21 |
| Total Debt / Capitalization | 17.07 |
| Cash Flow / Debt | -0.98 |
| Interest Coverage | -32.85 |
Financial Efficiency
Return on equity (ROE) is -0.22% and return on capital (ROIC) is -22.31%.
| Return on Equity (ROE) | -0.22% |
| Return on Assets (ROA) | -0.18% |
| Return on Capital (ROIC) | -22.31% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -688.22K |
| Employee Count | 79 |
| Asset Turnover | 0 |
| Inventory Turnover | 679.62K |
Taxes
| Income Tax | -632.44K |
| Effective Tax Rate | 0.01 |
Stock Price Statistics
The stock price has increased by 178.47% in the last 52 weeks. The beta is 0.42, so Verona Pharma's price volatility has been higher than the market average.
| Beta | 0.42 |
| 52-Week Price Change | 178.47% |
| 50-Day Moving Average | 41.05 |
| 200-Day Moving Average | 26.45 |
| Relative Strength Index (RSI) | 60.95 |
| Average Volume (20 Days) | 1.10M |
Income Statement
| Revenue | n/a |
| Gross Profit | -679.62K |
| Operating Income | -67.83M |
| Net Income | -54.37M |
| EBITDA | -52.47M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.54 |
Balance Sheet
The company has 271.77M in cash and 51.33M in debt, giving a net cash position of 220.44M.
| Cash & Cash Equivalents | 271.77M |
| Total Debt | 51.33M |
| Net Cash | 220.44M |
| Retained Earnings | -388.43M |
| Total Assets | 381.82M |
| Working Capital | 336.30M |
Cash Flow
In the last 12 months, operating cash flow was -50.22M and capital expenditures 4.07, giving a free cash flow of -50.22M.
| Operating Cash Flow | -50.22M |
| Capital Expenditures | 4.07 |
| Free Cash Flow | -50.22M |
| FCF Per Share | -0.63 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VRNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -1.11% |
| FCF Yield | -1.27% |
Analyst Forecast
The average price target for VRNA is $44, which is -9.3% lower than the current price. The consensus rating is "Buy".
| Price Target | $44 |
| Price Target Difference | -9.3% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Scores
| Altman Z-Score | 6.8 |
| Piotroski F-Score | 3 |